{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T12:09:38Z","timestamp":1769256578822,"version":"3.49.0"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","funder":[{"name":"Health \u223c Holland","award":["TKI-LSH_DT2021-RUMC"],"award-info":[{"award-number":["TKI-LSH_DT2021-RUMC"]}]},{"name":"Health \u223c Holland","award":["R0006655"],"award-info":[{"award-number":["R0006655"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Eculizumab is effective in treating paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. Given its high cost and the clinical risks associated with undertreatment or overtreatment, dose individualization is essential. Model-informed precision dosing can optimize therapy using pharmacokinetic (PK) model predictions. This study conducted a primarily internal validation to evaluate the predictive performance of a previously published PK model of eculizumab for model-informed precision dosing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>The model's ability to predict future free trough concentrations was assessed using retrospective data from therapeutic drug monitoring. Acceptable bias and precision were defined as mean prediction error and normalized root mean square error less than 25%. Dose adjustments were evaluated based on target trough concentrations of 50 \u00b5g\/mL for dose escalation and 200 \u00b5g\/mL for interval extension.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>The model adequately predicted future trough concentrations. In patients with paroxysmal nocturnal hemoglobinuria, bias and precision were \u22123.0% and 10.3%, respectively, when using one trough concentration; \u22128.4% and 24.9%, respectively, when using a trough and a peak concentration; and \u22124.7% and 16.3%, respectively, when using two trough concentrations. In patients with atypical hemolytic uremic syndrome, bias and precision were 6.1% and 35.5%, respectively, when using one trough concentration; 15.1% and 25.7%, respectively, when using a trough and a peak concentration; and 11.2% and 23.2%, respectively, when using two trough concentrations. The model's predictions led to correct dose recommendations for &gt;80% of patients in most analyses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>These results demonstrate that the eculizumab PK model can predict future trough concentrations with acceptable bias and precision.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001442","type":"journal-article","created":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T05:01:15Z","timestamp":1769144475000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Tailoring Eculizumab Treatment: Evaluation of Model-Informed Precision Dosing for Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria and Atypical Hemolytic Uremic Syndrome"],"prefix":"10.1097","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-0441-4514","authenticated-orcid":false,"given":"Astrid","family":"Heida","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Radboud Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, the Netherlands;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mendy","family":"ter Avest","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Radboud Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, the Netherlands;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ron J.","family":"Keizer","sequence":"additional","affiliation":[{"name":"Insight Rx, San Francisco, California;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole C. A. J.","family":"van de Kar","sequence":"additional","affiliation":[{"name":"Department of Pediatric Nephrology, Radboud University Medical Center, Nijmegen, the Netherlands;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saskia M. C.","family":"Langemeijer","sequence":"additional","affiliation":[{"name":"Departments of Hematology and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jack F. M.","family":"Wetzels","sequence":"additional","affiliation":[{"name":"Nephrology, Radboud University Medical Center, Nijmegen, the Netherlands."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rob E.","family":"Aarnoutse","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Radboud Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, the Netherlands;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nynke G. L.","family":"Jager","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Radboud Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, the Netherlands;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rob","family":"ter Heine","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Radboud Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, the Netherlands;"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2026,1,23]]},"reference":[{"key":"R2-20260123","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/bjh.12347","article-title":"Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria","volume":"162","author":"Hillmen","year":"2013","journal-title":"Br J Haematol"},{"key":"R3-20260123","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1053\/j.ajkd.2013.07.011","article-title":"Insights from the use in clinical practice of eculizumab in adult patients with atypical hemolytic uremic syndrome affecting the native kidneys: an analysis of 19 cases","volume":"63","author":"Fakhouri","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"R4-20260123","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s12882-019-1314-1","article-title":"Outcomes in patients with atypical hemolytic uremic syndrome treated with eculizumab in a long-term observational study","volume":"20","author":"Menne","year":"2019","journal-title":"BMC Nephrol"},{"key":"R5-20260123","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.kint.2015.11.026","article-title":"Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome","volume":"89","author":"Greenbaum","year":"2016","journal-title":"Kidney Int"},{"key":"R6-20260123","doi-asserted-by":"crossref","first-page":"6786","DOI":"10.1182\/blood-2011-02-333997","article-title":"Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival","volume":"117","author":"Kelly","year":"2011","journal-title":"Blood"},{"key":"R8-20260123","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1016\/j.jval.2024.03.068","article-title":"P42 budget impact analysis of eculizumab biosimilar for treatment of paroxysmal nocturnal hemoglobinuria from public Hospital perspective in 2023","volume":"27","author":"Robin","year":"2024","journal-title":"Value Health"},{"key":"R9-20260123","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/cpt.686","article-title":"Eculizumab dosing regimen in atypical HUS: possibilities for individualized treatment","volume":"102","author":"Volokhina","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"R10-20260123","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1080\/19420862.2015.1086049","article-title":"Therapeutic drug monitoring of eculizumab: rationale for an individualized dosing schedule","volume":"7","author":"Gatault","year":"2015","journal-title":"MAbs"},{"key":"R11-20260123","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1182\/blood-2014-03-560540","article-title":"Assessing complement blockade in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab","volume":"125","author":"Peffault de Latour","year":"2015","journal-title":"Blood"},{"key":"R12-20260123","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1111\/bcp.14627","article-title":"Feasibility and safety of tailored dosing schedule for eculizumab based on therapeutic drug monitoring: lessons from a prospective multicentric study","volume":"87","author":"Passot","year":"2021","journal-title":"Br J Clin Pharmacol"},{"key":"R13-20260123","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1093\/ndt\/gfac056","article-title":"Proposal for individualized dosing of eculizumab in atypical haemolytic uraemic syndrome: patient friendly and cost-effective","volume":"38","author":"Ter Avest","year":"2023","journal-title":"Nephrol Dial Transpl"},{"key":"R14-20260123","doi-asserted-by":"crossref","first-page":"759","DOI":"10.2215\/CJN.0000000000000145","article-title":"Proteinuria and exposure to eculizumab in atypical hemolytic uremic syndrome","volume":"18","author":"Ter Avest","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"key":"R15-20260123","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1007\/s00277-024-06086-z","article-title":"Management of paroxysmal nocturnal hemoglobinuria with low-level hemolysis in pregnancy-a report of two cases","volume":"104","author":"Riedl","year":"2025","journal-title":"Ann Hematol"},{"key":"R16-20260123","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.ekir.2018.12.014","article-title":"Pregnancy in a kidney transplant woman under treatment with eculizumab for atypical hemolytic uremic syndrome: is it safe?","volume":"4","author":"Duval","year":"2019","journal-title":"Kidney Int Rep"},{"key":"R17-20260123","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1016\/j.ekir.2019.08.020","article-title":"Use of eculizumab during pregnancy in kidney transplant recipients with atypical HUS","volume":"4","author":"Cheung","year":"2019","journal-title":"Kidney Int Rep"},{"key":"R18-20260123","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1002\/psp4.12353","article-title":"Model-informed precision dosing at the bedside: scientific challenges and opportunities","volume":"7","author":"Keizer","year":"2018","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"R19-20260123","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1111\/bcp.16335","article-title":"Recommended approaches for integration of population pharmacokinetic modelling with precision dosing in clinical practice","volume":"91","author":"Berezowska","year":"2025","journal-title":"Br J Clin Pharmacol"},{"key":"R20-20260123","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1007\/s40262-025-01536-x","article-title":"Model-informed precision dosing of eculizumab in patients with paroxysmal nocturnal hemoglobinuria","volume":"64","author":"Ter Avest","year":"2025","journal-title":"Clin Pharmacokinet"},{"key":"R21-20260123","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1111\/bcp.16019","article-title":"Eculizumab dose tapering should take into account the nonlinearity of its pharmacokinetics","volume":"90","author":"Le Tilly","year":"2024","journal-title":"Br J Clin Pharmacol"},{"key":"R22-20260123","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1007\/s00228-024-03703-8","article-title":"Population pharmacokinetic, pharmacodynamic and efficacy modeling of SB12 (proposed eculizumab biosimilar) and reference eculizumab","volume":"80","author":"Lee","year":"2024","journal-title":"Eur J Clin Pharmacol"},{"key":"R23-20260123","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ekir.2022.10.013","article-title":"Early eculizumab withdrawal in patients with atypical hemolytic uremic syndrome in native kidneys is safe and cost-effective: results of the CUREiHUS Study","volume":"8","author":"Bouwmeester","year":"2023","journal-title":"Kidney Int Rep"},{"key":"R24-20260123","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1007\/s00467-018-4091-3","article-title":"Eculizumab in atypical hemolytic uremic syndrome: strategies toward restrictive use","volume":"34","author":"Wijnsma","year":"2019","journal-title":"Pediatr Nephrol"},{"key":"R25-20260123","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/BF01060893","article-title":"Some suggestions for measuring predictive performance","volume":"9","author":"Sheiner","year":"1981","journal-title":"J Pharmacokinet Biopharm"},{"key":"R26-20260123","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s40262-023-01233-7","article-title":"External evaluation of population pharmacokinetic models for precision dosing: current state and knowledge gaps","volume":"62","author":"El Hassani","year":"2023","journal-title":"Clin Pharmacokinet"},{"key":"R27-20260123","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1007\/s40262-023-01271-1","article-title":"Comment on: \u201cexternal Evaluation of Population Pharmacokinetic Models for Precision Dosing: current State and Knowledge Gaps\u201d","volume":"62","author":"Lv","year":"2023","journal-title":"Clin Pharmacokinet"},{"key":"R28-20260123","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0169-7439(99)00027-1","article-title":"Estimating the uncertainty in estimates of root mean square error of prediction: application to determining the size of an adequate test set in multivariate calibration","volume":"49","author":"Faber","year":"1999","journal-title":"Chemom Intell Lab Syst"},{"key":"R29-20260123","doi-asserted-by":"crossref","first-page":"269","DOI":"10.5414\/CP204176","article-title":"A randomized, double-blind, three-arm, parallel group, single-dose phase I study to evaluate the pharmacokinetic similarity between SB12 (a proposed eculizumab biosimilar) and eculizumab (Soliris) in healthy subjects","volume":"60","author":"Lee","year":"2022","journal-title":"Int J Clin Pharmacol Ther"},{"key":"R30-20260123","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/ejh.13411","article-title":"A randomized, double-blind, single-dose, three-arm, parallel group study to determine pharmacokinetic similarity of ABP 959 and eculizumab (Soliris\u00ae) in healthy male subjects","volume":"105","author":"Chow","year":"2020","journal-title":"Eur J Haematol"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001442","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T05:01:19Z","timestamp":1769144479000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001442"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,23]]},"references-count":28,"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001442","relation":{},"ISSN":["0163-4356","1536-3694"],"issn-type":[{"value":"0163-4356","type":"print"},{"value":"1536-3694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,23]]},"assertion":[{"value":"2025-10-01","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-24","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}